Stùa-Birketvedt et al
1 recently published in this journal the weight loss data produced by treating obese patients with cimetidine for 12 weeks. Very little has previously been published on a such surprising and inexplicable effect of cimetidine, a H 2 receptor antagonist used routinely for the treatment of gastroduodenal ulcers and other peptic disorders. The recent paper by Stùa-Birketvedt et al, 1 cites only one previous human obesity study, 2 and this paper was also authored by Stùa-Birketvedt. This shows that the authors have failed to explore or cite the relevant clinical literature since our cimetidine trial, being the third published randomised clinical trial on cimetidine for treatment of human obesity, 3 is not mentioned. This is particularly surprising given that our paper appeared in the same issue of BMJ as the 1993 paper by Stùa-Birketvedt 2 and could hardly have escaped her attention. Stùa-Birketvedt, 2 found a mean excess weight loss of 7.3 kg (95% con®dence limits 6.5 ± 8.3 kg) in the cimetidine group compared to placebo. We found absolutely no signi®cant effect of cimetidine on body weight (mean 7 0.2 kg, 95% con®dence limits 7 2.0 kg ± 1.5 kg) in our similar trial of equal duration (8 weeks), 3 but this information has been ignored by Stùa-Birketvedt et al. 1 The two 1993 papers, 2,3 were published together with a note from the Editor of BMJ 4 and an editorial by Garrow. 5 Although neither provided any explanation for the markedly different weight loss outcomes, Garrow did note some peculiarities from the Stùa-Birketvedt study. 2 Stùa-Birketvedt and coworkers 1 now report a mean weight loss difference of 3.7 kg in equally obese patients who, in addition, had Type 2 diabetes. In both of the 1993 series 2,3 cimetidine was given as suspension, 200 mg three times daily, but in recent series as 400 mg (suspension?) three times daily. In the 1993 studies 2,3 cimetidine or placebo was given as adjunct to a 5 MJ diet and a ®bre supplement, whereas patients in the recent study 1 were instucted`to follow their own diet or eat less if not hungry'. The less formal diet led to an only marginally lower weight loss in the placebo group (1.3 kg) compared to the placebo group of the 1993 Stùa-Birketvedt series (2.2 kg). 2 Thus, we have got three randomised clinical trials with highly different outcomes that do not appear explained by minor variations in patient selection, duration, dosage and diet. Further, it has not hitherto been the general clinical impression that patients taking cimetidine for peptic desease lose weight. The pharmacological industry has seemingly not found it worthwhile to investigate cimetidine further as a weight reducing drug. In this context one cannot but question why the negative report 3 is not cited, and it puzzles us that the referee system of International Journal of Obesity has accepted the recent Stùa-Birketvedt publication in its present form.
